<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
The Liposome Company, Inc.
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-14887 22-2370691
- ------------------------------- ------------------------ ----------------------------
(State or other jurisdiction of (Commission file number) (IRS employer identification
incorporation) number)
</TABLE>
One Research Way
Princeton Forrestal Center
Princeton, New Jersey 08540-6619
- ---------------------------------------- ------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609)452-7060
Former name or former address, if changed since last report: None
Exhibit Index is on Page 3
Page 1 of 5
<PAGE>
Item 5. Other Events.
On June 25, 1997, The Liposome Company, Inc. (the "Company")
issued a press release announcing the results of a Phase III clinical trial of
Ventus(TM), a liposomal form of prostaglandin E1, in acute respiratory distress
syndrome. A copy of the press release is filed as an exhibit to this report.
Item 7. Exhibits.
Exhibit No. Description
20(a) Copy of the Company's press release of June 25, 1997 regarding
results of the Ventus(TM) Phase III clinical trial.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused behalf this registration statement to be signed on
its by the undersigned, thereunto duly authorized.
Date: June 27, 1997
THE LIPOSOME COMPANY, INC.
By: /s/ CHARLES A. BAKER
-------------------------
Name: Charles A. Baker
Title: Chairman and Chief
Executive Officer
<PAGE>
EXHIBIT INDEX
Sequentially Numbered
Exhibit No. Description Page
20(a) Copy of the Company's press release 4
dated June 25, 1997
<PAGE>
FOR IMMEDIATE RELEASE
Contact:
The Liposome Company, Inc.
Brooks Boveroux, Vice President
(609) 452-7060
Noonan Russo Communications
(212) 696-4455
Ernie Knewitz (media) ext. 204
Barbara Lindheim (investor) ext. 237
U.S. PHASE III STUDY OF VENTUS(TM) SHOWS NO DIFFERENCE
BETWEEN DRUG AND PLACEBO IN TREATMENT OF ARDS
Princeton, NJ -- June 25, 1997 -- The Liposome Company, Inc. (Nasdaq: LIPO)
today announced the results of its Phase III study of Ventus(TM) in the
treatment of Acute Respiratory Distress Syndrome (ARDS). The Company's analysis
of the two arms of the study showed no significant difference between patients
receiving Ventus(TM) or placebo either in reducing the time on mechanical
ventilation or in 28 day mortality. No safety concerns for the drug were
identified.
"We are very disappointed in the results of this study," said Charles A. Baker,
Chairman and Chief Executive Officer. "We will continue to evaluate the drug to
determine whether it can play a role in the treatment of patients with ARDS. We
will also continue to evaluate whether it may be useful in other clinical
settings."
Mr. Baker continued, "In addition to our work in the area of inflammation, the
Company has developed a franchise in cancer treatment. ABELCET(R) is being
marketed by the Company to treat systemic fungal infections in immunocompromised
patients, the vast majority of whom have undergone cancer treatment. Other
oncology products in development include TLC D-99, which is in two Phase III
clinical studies as a first-line treatment for metastatic breast cancer, and TLC
ELL-12, a novel therapeutic that is in pre-clinical testing."
<PAGE>
The Liposome Company is a broad-based biopharmaceutical company developing and
marketing products based on its knowledge of lipid technology. ABELCET(R)
(Amphotericin B Lipid Complex Injection) is marketed in the U.S. and other
countries for the treatment of severe systemic fungal infections. TLC D-99 and
other products are being developed to treat various cancers. Research is being
conducted in the area of bioactive lipids that may have therapeutic activity.
Except for historical information, this press release contains
forward-looking statements that involve risks and uncertainties,
including but not limited to statements regarding the possibility of
developing or commercializing Ventus(TM), TLC D-99, TLC ELL-12, or
any other product. While these statements reflect our best current
judgment, they are subject to risks and uncertainties that could
cause actual results to vary, including the risk factors identified
from time to time in the Company's SEC filings.
This release is also available at http:\\www.lipo.com
####
